3//SEC Filing
KKR Genetic Disorder L.P. 3
Accession 0000899243-19-018455
CIK 0001743881other
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 6:10 PM ET
Size
27.6 KB
Accession
0000899243-19-018455
Insider Transaction Report
Form 3
ROBERTS GEORGE R
10% Owner
Holdings
- (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying) - (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying)
KKR Management Holdings L.P.
10% Owner
Holdings
- (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
KKR Management Holdings Corp
10% Owner
Holdings
- (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
KKR & Co. L.P.
10% Owner
Holdings
- (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
KRAVIS HENRY R
10% Owner
Holdings
- (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
KKR Genetic Disorder GP LLC
10% Owner
Holdings
- (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying) - (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying)
KKR Group Holdings Corp.
10% Owner
Holdings
- (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
KKR Management LLC
10% Owner
Holdings
- (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
KKR Genetic Disorder L.P.
10% Owner
Holdings
- (indirect: See Footnotes)
Series B Preferred Units
Exercise: $0.00→ Common Stock (15,859,312 underlying) - (indirect: See Footnotes)
Series C Preferred Units
Exercise: $0.00→ Common Stock (8,215,295 underlying) - (indirect: See Footnotes)
Series D Preferred Units
Exercise: $0.00→ Common Stock (10,178,954 underlying)
Footnotes (5)
- [F1]Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all outstanding units in BridgeBio Pharma LLC (the "LLC") will be exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer will be merged with and into the LLC, and shares of Common Stock will be allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it is liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date.
- [F2]Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Persons.
- [F3]Represents shares of Common Stock issuable in the Reorganization in exchange for Series C Preferred Units in the LLC held by the Reporting Persons.
- [F4]Represents shares of Common Stock issuable in the Reorganization in exchange for Series D Preferred Units in the LLC held by the Reporting Persons.
- [F5]The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001780408
Filing Metadata
- Form type
- 3
- Filed
- Jun 26, 8:00 PM ET
- Accepted
- Jun 27, 6:10 PM ET
- Size
- 27.6 KB